An Assessment of the Occurrence of Hypothyroidism in Patients Treated With RAI for Hyperthyroidism.
NCT ID: NCT04663451
Last Updated: 2021-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2020-09-11
2021-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the past, either calculated or fixed doses of 131I have been used to treat hyperthyroidism. The supposed advantage of a calculated dose compared to a fixed dose is the lowering of hypothyroidism frequency. However, various research papers have contradicted this statement.
Antithyroid drugs and RAI therapy have been widely used in the past, either in combination, or independent from one another. This has been done primarily in older patients, to reduce the risk of exacerbation of hyperthyroid symptoms after initiation of RAI.
The use of propylthiouracil has been shown to decrease the response rate after RAI due to radioprotective effects.
The use of methimazole and carbimazole did not have a negative effect on treatment failure, as long as the medication was discontinued various days before RAI administration. Although this statement is contested in other studies.
It is interesting to evaluate retrospective data of patients treated with RAI to evaluate prognostic factors of treatment respons and post RAI hypothyroidism.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Affecting Timing of Hypothyroidism Following Radioactive Iodine Therapy Patients With Graves Disease
NCT05643365
Three-Year Follow-up of Radioiodine Therapy for Goitre
NCT00509483
Follow-up Study of the RAI-Treated Hyperthyroid Patients
NCT00471458
Block-replacement Therapy During Radioiodine Therapy
NCT00150124
rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter
NCT00275171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Toxic Nodule
Hyperthyroid patients with underlying toxic nodule
radioacive iodine therapy
Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
Toxic multinodular goiter
Hyperthyroid patients with underlying toxic multinodular goiter
radioacive iodine therapy
Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
radioacive iodine therapy
Hyperthyroid patients who have undergone radioactive iodine treatment to cure them from their hyperthyroidism.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prior thyroid surgery
* Prior RAI treatment
* Patients with thyroiditis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitair Ziekenhuis Brussel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brigitte Velkeniers
Head of the department of Internal Medicine and Endocrinology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Corina Andreescu, Doctorate
Role: PRINCIPAL_INVESTIGATOR
Universitair Ziekenhuis Brussel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitair Ziekenhuis Brussel
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019/435
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.